Pharmacokinetics of methotrexate in continuous ambulatory peritoneal dialysis
The pharmacokinetics of methotrexate and its 7-hydroxy metabolite were studied in a patient undergoing continuous ambulatory peritoneal dialysis. A biphasic plasma-disappearance pattern of methotrexate was observed, with half-lives of 3.5 and 29 hours. The 7-hydroxy metabolite accumulated and showed a very slow rate of elimination, with an estimated final elimination half-life of over 120 hours. The mean peritoneal clearance rate of methotrexate was 0.13 l/h (range 0.05–0.20 l/h), dwell times significantly influenced the clearance rate. Strict monitoring of the methotrexate level, even after low doses, is necessary in continuous ambulatory peritoneal dialysis patients, to prevent serious bone marrow toxicity.
KeywordsMetabolism Methotrexate Peritoneal dialysis, continuous ambulatory
Unable to display preview. Download preview PDF.
- 1.Lankelma J, Van der Kleijn E, Termond EF. Assay of methotrexate and 7-OH methotrexate by HPLC and its applications to clinical pharmacokinetics. In: Pinedo HM, ed. Clinical pharmacology of anti-neoplastic drugs. Amsterdam: Elsevier, 1978:13–28.Google Scholar
- 2.Edelman J, Biggs DF, Janali F, Russell AS. Low dose methotrexate kinetics in arthritis. Clin Pharmacol Ther 1984;35:382–6.Google Scholar
- 3.Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 1987;3:1–13.Google Scholar
- 4.Huffmann DH, Won SH, Azamoff DL, Hoogstraten B. Pharmacokinetics of methotrexate. Clin Pharmacol Ther 1973;14:572–9.Google Scholar
- 5.Janknegt R, Koelman JH. Drug therapy in continuous ambulatory peritoneal dialysis patients. Pharm Weekbl [Sci] 1987;9:104–9.Google Scholar
- 6.Martea M, Hekster YA, Vree TB, Voefs AJ, Berden JHM. Pharmacokinetics of cefradine, sulfamethoxazole and trimethoprim and their metabolites in a patient with peritonitis, undergoing continuous ambulatory peritoneal dialysis. Pharm Weekbl [Sci] 1987;9:110–6.Google Scholar